KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch ...
Camrelizumab with carboplatin and nab-paclitaxel shows potential as a first-line treatment for ES-SCLC, with promising survival rates. The study identified biomarkers, including MUC17 alterations and ...
A retrospective review of New Zealand patients with advanced ovarian cancer treated with dose dense chemotherapy. Lymph node involvement pattern and survival differences of FIGO IIIC[1] and FIGO IIIA1 ...
TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN). This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, ...
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study ...
Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall ...
Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up. Adding ...
SAN ANTONIO — The addition of carboplatin to a standard neoadjuvant chemotherapy regimen significantly improves disease-free or event-free survival in patients with early-stage triple-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results